Erste Asset Management GmbH Purchases Shares of 1,058,378 Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Erste Asset Management GmbH bought a new position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1,058,378 shares of the company's stock, valued at approximately $6,192,000. Erste Asset Management GmbH owned about 1.94% of Voyager Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of VYGR. China Universal Asset Management Co. Ltd. boosted its position in Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock worth $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Voyager Therapeutics during the 3rd quarter worth $74,000. SG Americas Securities LLC purchased a new position in shares of Voyager Therapeutics in the 2nd quarter worth about $85,000. Victory Capital Management Inc. grew its position in Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company's stock valued at $102,000 after buying an additional 1,630 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in Voyager Therapeutics during the second quarter worth about $128,000. 48.03% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.53% of the company's stock.

Voyager Therapeutics Stock Performance

NASDAQ VYGR traded down $0.36 during trading hours on Tuesday, hitting $6.57. The company had a trading volume of 821,612 shares, compared to its average volume of 640,833. The firm has a market capitalization of $358.92 million, a price-to-earnings ratio of 9.25 and a beta of 0.90. Voyager Therapeutics, Inc. has a 52 week low of $5.19 and a 52 week high of $11.72. The firm has a 50 day simple moving average of $6.54 and a 200 day simple moving average of $7.26.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the business earned ($0.59) earnings per share. On average, research analysts forecast that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VYGR. Leerink Partnrs upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. StockNews.com raised Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Monday, November 18th. Canaccord Genuity Group restated a "buy" rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Citigroup initiated coverage on Voyager Therapeutics in a research note on Monday. They set a "buy" rating and a $12.00 price target for the company. Finally, Wedbush initiated coverage on Voyager Therapeutics in a research note on Friday. They issued an "outperform" rating and a $11.00 price objective on the stock. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics currently has an average rating of "Buy" and a consensus target price of $17.00.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.